Erlotinib Hydrochloride in Preventing Cancer in Patients With Precancerous Lesions of the Lung

NCT01013831 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

60

Enrollment

NIH

Sponsor class

Conditions

Dysplasia
Metaplasia
Pulmonary Precancerous Condition

Interventions

DRUG: Erlotinib Hydrochloride
OTHER: Laboratory Biomarker Analysis
OTHER: Pharmacological Study

Sponsor

National Cancer Institute (NCI)